Trial Profile
A Randomized, Double Blind, Placebo Controlled, Phase II Study of KUC-7483 in Patients With Overactive Bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2009
Price :
$35
*
At a glance
- Drugs Ritobegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 10 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2008 New trial record.